Inspirations

[ksuave]

DCTH

National Cancer Institute to Present Treatment Results With Delcath System at Multidisciplinary Cancer Meeting
Thursday January 20, 7:59 am ET


STAMFORD, Conn., Jan. 20 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH - News) was informed by H. Richard Alexander, MD, head of the NCI's Surgical Metabolism Section, that his colleague, Jeffrey Farma, MD, will present the preliminary results from treating 15 melanoma patients with the Delcath system to the 2005 Gastrointestinal Cancers Symposium in Hollywood, Florida January 27-29.
The three-day, multidisciplinary symposium on gastrointestinal cancers is co-sponsored by the American Society of Clinical Oncology, the American Gastroenterological Association, the American Society for Therapeutic Radiology and Oncology, and the Society of Surgical Oncology. This is the second consecutive year the meeting will be held and also marks the second year a presentation will be given on the use of the Delcath system.

The research team at the NCI which conducted the Phase I study being reported on at the meeting has since started Phase II clinical studies to provide further data to support the safety and efficacy claims that will form the basis of eventual applications for approval to the FDA.

The Delcath system delivers high-dose chemotherapy directly to the liver via the hepatic artery. As blood exits the liver, special Delcath filters trap the chemotherapy, protecting the rest of the body from excessive toxicity. The procedure is repeatable and less invasive than traditional ways of performing isolated perfusion to effect dose-directed therapy of specific body organs or regions.

"We're experiencing growing interest within the medical community to learn more about our cancer treatment," Delcath CEO M.S. Koly said. "Although we have completed several phases of clinical studies with multiple drugs to demonstrate the usefulness of the system, it is also critical that physicians throughout the country become knowledgeable about its benefits. The upcoming meeting is an important mechanism for doctors to discuss the Delcath system critically with their peers, and we are pleased the NCI Investigators continue to be invited to share their knowledge in this area."

Delcath is a developer of isolated perfusion technology for organ or region-specific delivery of therapeutic agents. Six U.S., and three foreign issued patents cover its technology. The company is headquartered in Stamford, CT.

This release contains "forward-looking statements" based on current expectations but involving known and unknown risks and uncertainties. Actual results or achievements may be materially different from those expressed or implied. Delcath plans and objectives are based on assumptions involving judgments with respect to future economic, competitive and market conditions, its ability to consummate, and the timing of, acquisitions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond its control. Therefore, there can be no assurance than any forward-looking statement will prove to be accurate.

Contact:
M.S. Koly Thomas Redington
Chief Executive Officer Redington, Inc.
Delcath Systems, Inc. 203/222-7399
203/323-8668 212/926-1733
http://www.delcath.com http://www.redingtoninc.com